Sichuan Huiyu Pharmaceutical Co Ltd
Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor injection in China and internationally. The company offers injection drug products, such as pemetrexed disodium, methrotraxate, docetaxel, azacitidine, oxaliplatin, cyclophosphamide, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, decitabine, palonosetron hydrochloride, plerixafor, levet… Read more
Sichuan Huiyu Pharmaceutical Co Ltd (688553) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.16 Billion CNY
Based on the latest financial reports, Sichuan Huiyu Pharmaceutical Co Ltd (688553) has total liabilities worth CN¥1.16 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sichuan Huiyu Pharmaceutical Co Ltd - Total Liabilities Trend (2017–2024)
This chart illustrates how Sichuan Huiyu Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sichuan Huiyu Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Sichuan Huiyu Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Malion New Materials Co Ltd
SHE:300586
|
China | CN¥1.44 Billion |
|
Ningbo Donly Co Ltd
SHE:002164
|
China | CN¥1.10 Billion |
|
Hwang Chang General Contractor Co Ltd
TW:2543
|
Taiwan | NT$9.41 Billion |
|
Luolai Home Textile Co Ltd
SHE:002293
|
China | CN¥2.53 Billion |
|
Changzhou Tenglong Auto Parts
SHG:603158
|
China | CN¥2.41 Billion |
|
Nan Pao Resins Chemical Co Ltd
TW:4766
|
Taiwan | NT$12.61 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Sichuan Huiyu Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sichuan Huiyu Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sichuan Huiyu Pharmaceutical Co Ltd (2017–2024)
The table below shows the annual total liabilities of Sichuan Huiyu Pharmaceutical Co Ltd from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.19 Billion | +30.84% |
| 2023-12-31 | CN¥911.22 Million | +63.17% |
| 2022-12-31 | CN¥558.44 Million | -2.20% |
| 2021-12-31 | CN¥571.01 Million | +23.79% |
| 2020-12-31 | CN¥461.26 Million | +2.20% |
| 2019-12-31 | CN¥451.33 Million | -7.89% |
| 2018-12-31 | CN¥490.02 Million | +16.14% |
| 2017-12-31 | CN¥421.94 Million | -- |